Type 1

Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes

Retrieved on: 
Mercoledì, Gennaio 25, 2023
Baton Rouge, Louisiana, Type 1 diabetes, ADI, Diabetes, Research, Edmonton protocol, ATRX, Type 1, Pancreas, Immune system, OTCQB, C-peptide, University, Patient, Insulin, Therapy, Pharmaceutical industry, Data

The Company and U of A are finalizing the details of the trial, which are expected to be released shortly.

Key Points: 
  • The Company and U of A are finalizing the details of the trial, which are expected to be released shortly.
  • The results of the study will also be utilized to optimize the dose range used in Adhera’s forthcoming Phase 2 multi-center clinical trial of MLR-1023 in Type 1 Diabetes.
  • We are honored to be collaborating with an institution of this stature,” said Dr. Zahed Subhan, Chief Executive Officer of Adhera Therapeutics.
  • Independent research has demonstrated robust therapeutic effects of MLR-1023 in Type 1 Diabetes preclinical models.

Genprex Signs Exclusive License to Additional Diabetes Technology with the University of Pittsburgh

Retrieved on: 
Giovedì, Gennaio 5, 2023
Cancer, Pancreas, University, Mouse, Insulin, Glucagon, MD, Type 1, AAV, Diabetes, Factor X, PDX1, Autoimmunity, Division, Wilfrid Sellars, Disease, Patient, Pediatrics, Type 2, Macrophage, Type 2 diabetes, Pitt, University of Pittsburgh School of Medicine, MAF (gene), Patent, Immune system, Human, Gene, Pharmaceutical industry

AUSTIN, Texas, Jan. 5, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement (the Agreement) with the University of Pittsburgh (Pitt), granting Genprex a worldwide, exclusive license to a patent application and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to gene therapy for Type 2 diabetes using the genes of the Pdx1 and MafA transcription factors. The preclinical technology, GPX-003, is believed to work by rejuvenating diminished beta cells to increase insulin expression by introducing transcription factors controlled by an insulin promoter.

Key Points: 
  • "This marks the Company's third technology license this year supporting our diabetes program, demonstrating the continued strengthening of our intellectual property portfolio, our diabetes program, and our position as a lead innovator in emerging diabetes gene therapies," said Rodney Varner, President and Chief Executive Officer of Genprex.
  • "We are thrilled to have secured multiple cutting edge technologies from Pitt that expand our diabetes gene therapy program and specifically target Type 1 and Type 2 diabetes."
  • Genprex recently announced a license agreement with the University of Pittsburgh for a preclinical technology that transforms macrophages enabling them to reduce autoimmune activity in Type 1 diabetes, a technology that could be complementary to the Company's GPX-002 diabetes technology.
  • More than 537 million people around the world have diabetes, and in the U.S. alone, there are 37.3 million people with diabetes.

Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes

Retrieved on: 
Mercoledì, Gennaio 4, 2023
Human, University, Protein, Autoimmunity, Wilfrid Sellars, Security (finance), Central European, Type 1, Annual report, Patient, Type 2, Food, Squamous cell carcinoma, Medicine, Immune system, Intellectual property, Large-cell lung carcinoma, Honda advanced technology, ATTD, Tumor suppressor gene, Growth, COVID-19, Food and Drug Administration Amendments Act of 2007, Division, Pediatric surgery, Conference, MAF (gene), AAV, MD, Gene, Mouse, Treatment, Pittsburgh, Uncertainty, Pancreas, Pediatrics, Risk, NSCLC, DO, International Conference on Emerging Infectious Diseases, Insulin, Research, Cancer, Pharmaceutical industry, Vaccine, Audit, Diabetes, PDX1

AUSTIN, Texas, Jan. 4, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators at the University of Pittsburgh will present preclinical data highlighting the therapeutic potential of Genprex's gene therapy for Type 1 diabetes at the 16th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2023) being held February 22-25 in Berlin, Germany and online.

Key Points: 
  • "ATTD 2023 presents an ideal opportunity for the results of this important study to be presented to the diabetes community.
  • The diabetes gene therapy approach is comprised of a novel infusion process that uses endoscopic delivery of an adeno-associated virus (AAV) vector to bring therapeutic genes directly to the pancreas.
  • Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options.
  • You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco

Retrieved on: 
Giovedì, Dicembre 15, 2022
Conference, Immunotherapy, Annual report, Clostridioides difficile infection, Genetic engineering, Mortality, Entrepreneurship, Biotechnology, Government, SAB, Degenerative disease, J. P. Morgan, Probability, United States Department of Defense, Type 1, MD, Form 10-K, Infection, Pandemic, IND, Patent, Clostridioides difficile (bacteria), Patient, Showcase, Pharmaceutical industry, Vaccine

The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.

Key Points: 
  • The conference is taking place Jan. 9-11 in San Francisco, in parallel with the J.P. Morgan 41st Annual Health Care Conference.
  • Alexandra Kropotova, MD, Executive Vice President, and Chief Medical Officer of SAB Biotherapeutics, will present at the Showcase on Tuesday, January 10 at 2:30pm PT.
  • SAB currently has multiple drug development programs underway and collaborations with the US government and global pharmaceutical companies.
  • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .

Panbela Receives Positive EMA Opinion on Orphan Designation for Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Retrieved on: 
Mercoledì, Dicembre 14, 2022
European Commission, PMI, Neoplasm, MSN, Peripheral neuropathy, Annual report, Retinopathy, Ovarian cancer, Neuroblastoma, Marketing, Type 1, Eflornithine, Cancer, Retinal detachment, COVID-19, European Medicines Agency, Colorectal cancer, EMA, Person, Atlas Shrugged: Part I, Food, FDA, Safety, Rectum, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Royal commission, Therapy, Sulindac, FAP, Doctor of Philosophy, ORR, Committee, Union, PDA, Patient, File, Bone marrow suppression, Pancreatic cancer, Colon, Stomach, Risk, Pharmaceutical industry, EU
Key Points: 

    SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock

    Retrieved on: 
    Mercoledì, Dicembre 7, 2022
    Immunotherapy, Annual report, Clostridioides difficile infection, Genetic engineering, Mortality, Warrant, Government, SAB, Degenerative disease, Probability, United States Department of Defense, Type 1, Form 10-K, Infection, Arcadia, Clostridioides, Pandemic, IND, Patent, United States securities regulation, Clostridioides difficile (bacteria), Patient, Security (finance), Vaccine, Pharmaceutical industry

    Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.

    Key Points: 
    • Existing SAB investors – including T. Denny Sanford, an experienced biotech investor and healthcare philanthropist -- as well as new institutional investors participated in the private placement.
    • The aggregate gross proceeds from the offering are approximately $7.9 million, based on the offering price of $1.08 which was the 5-day average closing price ending December 5, 2022, for each share of the Company's common stock plus one Warrant.
    • The Company expects to use net proceeds from the private placement to advance the Company’s pipeline of its first-in-class product candidates for Clostridioides difficile (C.
    • For more information on SAB, visit: https://www.SAb.bio/ and follow SAB on Twitter and LinkedIn .

    Dexcom G7 Receives FDA Clearance: The Most Accurate Continuous Glucose Monitoring System Cleared in the U.S.

    Retrieved on: 
    Giovedì, Dicembre 8, 2022
    FDA, Diabetes, Medical Devices, Health, Health Technology, Security (finance), Clarity, Warrior, Centers for Medicare & Medicaid Services, DXCM, Ecosystem, MD, Apple Watch, Compatibility, Type 1, Patient, CGM, Garmin, Internet, CES, FDA, Diabetes, Health care, Medicaid, Caregiver, Multimedia, G7, G6, Pharmacy, Insurance, Medicare, Medical device, Pharmaceutical industry, Recycling, Intermodal freight transport, Dexcom

    DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.

    Key Points: 
    • DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation Dexcom G7 Continuous Glucose Monitoring (CGM) System for people with all Types of diabetes ages two years and older.
    • And now that it has been cleared by the FDA, we look forward to making G7 commercially available in the coming months.
    • Dexcom G7 also offers a suite of customizable alerts that can warn of high or low glucose levels and help users spend more time in range.
    • If your glucose alerts and readings from Dexcom G7 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

    EVOQ Therapeutics to Collaborate with JDRF

    Retrieved on: 
    Martedì, Dicembre 13, 2022
    Therapy, Antigen, Immune system, JDRF, Immunotherapy, AMGEN, Partnership, Type 1, Patient, Degenerative disease, Research, ANN, Immune tolerance, Nanodisc, National Rural Development Partnership, Multimedia, Volunteering, Pharmaceutical industry, Vaccine, T1D

    ANN ARBOR, Mich., Dec. 13, 2022 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases, today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D). 

    Key Points: 
    • ANN ARBOR, Mich., Dec. 13, 2022 /PRNewswire/ -- EVOQ Therapeutics , Inc. (EVOQ), a biopharmaceutical company focused on the discovery and development of drugs to treat patients afflicted with autoimmune diseases, today announced a collaboration with JDRF for the development of a new drug platform for antigen-specific immune-tolerizing therapy against Type 1 diabetes (T1D).
    • Having demonstrated pre-clinical efficacy in multiple autoimmune diseases, EVOQ is enthusiastic to work closely with JDRF on Type 1 diabetes," said William Brinkerhoff, CEO at EVOQ Therapeutics.
    • "JDRF is thrilled to work alongside the dedicated team at EVOQ Therapeutics at this exciting time," said Joshua A. Vieth, Ph.D., director of research at JDRF.
    • EVOQ Therapeutics is advancing a pipeline of disease-specific immune modulators to treat patients afflicted with autoimmune diseases.

    Genprex to Present at Upcoming December Investor Conference

    Retrieved on: 
    Venerdì, Dicembre 2, 2022
    NSCLC, PDX1, Type 2, COVID-19, Insulin, MAF (gene), Human, Intellectual property, Pancreas, Tumor suppressor gene, Type 1, Diabetes, Large-cell lung carcinoma, Immune system, Cancer, Conference, Squamous cell carcinoma, Annual report, Risk, Growth, Q&A, Food, Food and Drug Administration Amendments Act of 2007, AAV, Protein, Autoimmunity, Patient, Security (finance), Gene, General counsel, Uncertainty, Pharmaceutical industry, Audit

    AUSTIN, Texas , Dec. 2, 2022 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its Executive Vice President, General Counsel and Chief Strategy Officer, Catherine Vaczy, will be providing an overview of the Company's gene therapies for cancer and diabetes at the following investor conference in December 2022.

    Key Points: 
    • Ms. Vaczy will be available for Q&A following the presentation and for in-person one-on-one meetings with investors at the RHK Disruptive Growth Conference.
    • Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes.
    • Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
    • You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all.

    Panbela Announces First Patients Enrolled in Europe for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

    Retrieved on: 
    Lunedì, Novembre 28, 2022
    COVID-19, Doctor of Philosophy, Retinal detachment, Colon, ORR, Union, Type 1, Sulindac, Bone marrow suppression, Rectum, Risk, Pancreatic cancer, Safety, Therapy, Cancer, Peripheral neuropathy, Patient, Neuroblastoma, Eflornithine, Annual report, File, MSN, PMI, Colorectal cancer, Neoplasm, Stomach, Retinopathy, Ovarian cancer, FAP, FDA, Pharmaceutical industry

    ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.

    Key Points: 
    • ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma.
    • Having European enrollment underway is highly encouraging as we continue to ramp up the trial.
    • The safety data and PMI profile observed in the previous Panbela-sponsored clinical trials provide support for continued evaluation of ivospemin in the ASPIRE trial.
    • In a Phase 3 clinical trial in patients with sporadic large bowel polyps, the combination prevented > 90% subsequent pre-cancerous sporadic adenomas versus placebo.